Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company's first and only commercial product is the Novavax COVID-19 vaccine. The company is also developing vaccines for influenza, respiratory syncytial virus (RSV), avian flu, shingles, Clostridioides difficile, and malaria.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| NVAX | NOVAVAX INC | 2025-10-16 21:33:38 | 8.49 | 0.01 | 0.12 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NVAX | 0001000694 | NOVAVAX INC | US6700024010 | 529900J4GJHPEPQ23205 | 222816046 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 700 QUINCE ORCHARD ROAD | GAITHERSBURG | MD | 20878 | UNITED STATES | US | 240-268-2000 | 700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD, 20878 | 700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD, 20878 | — | Biotechnology | 1987 | John C. Jacobs | 952 | https://www.novavax.com/ | 2,020,000,000 | 164,475,337 | 162,421,645 | Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company's first and only commercial product is the Novavax COVID-19 vaccine. The company is also developing vaccines for influenza, respiratory syncytial virus (RSV), avian flu, shingles, Clostridioides difficile, and malaria. | 2025-10-10 21:01:14 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 2,020,000,000 | 1,321,000,000 | 188.9843 | 160,844,197 | 20,891,054 | 14.9272 |
| 2023 | 699,000,000 | -3,311,000,000 | -82.5686 | 139,953,143 | 53,779,898 | 62.409 |
| 2022 | 4,010,000,000 | -11,687,000,000 | -74.4537 | 86,173,245 | 9,890,259 | 12.9652 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| John J. Trizzino | Chief Operating Officer, President | 2024 | 582,825 | 0 | 776,160 | 261,911 | 12,521 | 1,633,417 |
| Elaine O'Hara | EVP, Chief Strategy Officer | 2024 | 535,600 | 0 | 646,800 | 358,163 | 97,553 | 1,638,116 |
| John C. Jacobs | CEO, President | 2024 | 752,500 | 0 | 1,347,500 | 684,311 | 113,800 | 5,087,461 |
| James P. Kelly | Chief Financial Officer, EVP, Treasurer | 2024 | 545,900 | 0 | 948,640 | 321,229 | 13,720 | 1,829,489 |
| Mark J. Casey | Chief Legal Officer, EVP, Corporate Secretary | 2024 | 558,250 | 0 | 64,680 | 319,562 | 119,842 | 1,062,334 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 952 |
| 2023 | 1,543 |
| 2022 | 1,992 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 682,162,000 | 983,705,000 | 1,981,872,000 |
| Cost Of Revenue | 202,739,000 | 343,768,000 | 902,639,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 391,169,000 | 737,502,000 | 1,235,278,000 |
| General And Administrative Expenses | 337,185,000 | 468,946,000 | 488,691,000 |
| Operating Expenses | 931,093,000 | 1,550,216,000 | 2,626,608,000 |
| Operating Income | -248,931,000 | -566,511,000 | -644,736,000 |
| Net Income | -187,499,000 | -545,062,000 | -657,939,000 |
| Earnings Per Share Basic | -1.23 | -5.41 | -8.42 |
| Earnings Per Share Diluted | -1.23 | -5.41 | -8.42 |
| Weighted Average Shares Outstanding Basic | 152,190,000 | 100,768,000 | 78,183,000 |
| Weighted Average Shares Outstanding Diluted | 152,190,000 | 100,768,000 | 78,183,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 530,230,000 | 568,505,000 | 1,336,883,000 |
| Marketable Securities Current | 392,888,000 | — | — |
| Accounts Receivable | 108,285,000 | 297,240,000 | 82,375,000 |
| Inventories | 8,749,000 | 41,696,000 | 36,683,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 21,888,000 | 155,726,000 | 76,374,000 |
| Total Assets Current | 1,128,942,000 | 1,143,888,000 | 1,703,391,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 138,413,000 | 305,771,000 | 294,247,000 |
| Other Assets Non Current | 24,000,000 | 35,159,000 | 28,469,000 |
| Total Assets Non Current | 299,998,000 | 653,602,000 | 555,288,000 |
| Total Assets | 1,560,418,000 | 1,797,490,000 | 2,258,679,000 |
| Accounts Payable | 41,579,000 | 132,610,000 | 216,517,000 |
| Deferred Revenue | 675,067,000 | 241,310,000 | 370,137,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 219,596,000 | 861,408,000 | 930,055,000 |
| Total Liabilities Current | 1,154,416,000 | 1,635,138,000 | 2,459,944,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 359,614,000 | 33,130,000 | 55,695,000 |
| Total Liabilities Non Current | 1,029,843,000 | 879,279,000 | 432,813,000 |
| Total Liabilities | 2,184,259,000 | 2,514,417,000 | 2,892,757,000 |
| Common Stock | 1,619,000 | 1,405,000 | 868,000 |
| Retained Earnings | -5,008,450,000 | -4,820,951,000 | -4,275,889,000 |
| Accumulated Other Comprehensive Income | -22,559,000 | 2,722,000 | -6,377,000 |
| Total Shareholders Equity | -623,841,000 | -716,927,000 | -634,078,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 48,496,000 | 41,225,000 | 29,054,000 |
| Share Based Compensation Expense | 48,152,000 | 85,357,000 | 130,300,000 |
| Other Non Cash Income Expense | 21,809,000 | 7,042,000 | 21,903,000 |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | -12,914,000 | 74,457,000 | 477,801,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -385,626,000 | -378,805,000 | 913,399,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -87,263,000 | -713,967,000 | -415,937,000 |
| Purchases Of Marketable Securities | 825,593,000 | 0 | 0 |
| Sales Of Marketable Securities | 443,551,000 | 0 | 0 |
| Acquisition Of Property Plant And Equipment | — | — | — |
| Acquisition Of Business | — | — | 0 |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -204,038,000 | -58,806,000 | -92,985,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 263,272,000 | 360,243,000 | 249,230,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 260,583,000 | 4,466,000 | 324,988,000 |
| Change In Cash | -38,518,000 | -765,035,000 | -179,414,000 |
| Cash At End Of Period | 530,230,000 | 568,505,000 | 1,336,883,000 |
| Income Taxes Paid | 949,000 | 190,000 | 17,980,000 |
| Interest Paid | 17,572,000 | 17,349,000 | 18,035,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -1.23 | -5.41 | -8.42 |
| Price To Earnings Ratio | -6.5366 | -0.8872 | -1.2209 |
| Earnings Growth Rate | -77.2643 | -35.7482 | -64.0785 |
| Price Earnings To Growth Ratio | 0.0846 | 0.0248 | 0.0191 |
| Book Value Per Share | -4.0991 | -7.1146 | -8.1102 |
| Price To Book Ratio | -1.9614 | -0.6747 | -1.2675 |
| Ebitda | -127,624,000 | -489,231,000 | -591,025,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | -118,862,000 | 52,749,000 | 94,605,000 |
| Free Cash Flow | 31,599,000 | -766,716,000 | -510,542,000 |
| Return On Equity | 0.3006 | 0.7603 | 1.0376 |
| One Year Beta | 1.8542 | 1.1947 | 2.3969 |
| Three Year Beta | 2.0879 | 1.8416 | 1.1758 |
| Five Year Beta | 1.2209 | 1.1336 | 1.2012 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| MCGLYNN MARGARET G | Director | 2025-06-20 | 28,326 | A | 28,326 |
| MCGLYNN MARGARET G | Director | 2025-06-20 | 18,884 | A | 18,884 |
| Alton Gregg H | Director | 2025-06-20 | 28,326 | A | 28,326 |
| Alton Gregg H | Director | 2025-06-20 | 18,884 | A | 18,884 |
| DOUGLAS RICHARD | Director | 2025-06-20 | 28,326 | A | 28,326 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Pat Roberts | Senator | 2020-11-05 | Sale (Full) | 2020-10-13 | Spouse | $1,001 - $15,000 |
| Pat Roberts | Senator | 2020-08-30 | Purchase | 2020-08-17 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Blue Trust, Inc. | 2025-09-30 | 434 | 50 | 8.68 |
| CWM, LLC | 2025-09-30 | 12,000 | 1,408 | 8.5227 |
| Vontobel Holding Ltd. | 2025-09-30 | 539,560 | 62,233 | 8.67 |
| Bulwark Capital Corp | 2025-09-30 | 5,289 | 610 | 8.6705 |
| Farther Finance Advisors, LLC | 2025-09-30 | 221,267 | 25,521 | 8.67 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| ETFis Series Trust I | 2025-07-31 | Virtus LifeSci Biotech Products ETF | BBP | 62,153 | 413,317.45 | 1.6771 |
| Advisors' Inner Circle Fund III | 2025-07-31 | I Shares | KCXIX | 689 | 4,581.85 | 0.0019 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2025-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 55,067 | 366,195.55 | 0.0154 |
| Global X Funds | 2025-07-31 | Global X Russell 2000 ETF | RSSL | 76,603 | 509,409.95 | 0.0387 |
| FIDELITY CONCORD STREET TRUST | 2025-07-31 | Fidelity ZERO Total Market Index Fund | FZROX | 74,146 | 493,070.9 | 0.0017 |